Protara Therapeutics, Inc.
TARA
$6.19
$0.284.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.77M | 19.87M | 18.32M | 17.45M | 17.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 59.78M | 57.35M | 51.43M | 49.15M | 45.88M |
| Operating Income | -59.78M | -57.35M | -51.43M | -49.15M | -45.88M |
| Income Before Tax | -52.90M | -50.86M | -45.42M | -44.60M | -42.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -52.90 | -50.86 | -45.42 | -44.60 | -42.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.90M | -50.86M | -45.42M | -44.60M | -42.05M |
| EBIT | -59.78M | -57.35M | -51.43M | -49.15M | -45.88M |
| EBITDA | -59.43M | -57.01M | -51.10M | -48.82M | -45.53M |
| EPS Basic | -1.44 | -1.63 | -1.73 | -2.41 | -2.82 |
| Normalized Basic EPS | -0.90 | -1.02 | -1.08 | -1.50 | -1.76 |
| EPS Diluted | -1.44 | -1.63 | -1.73 | -2.41 | -2.82 |
| Normalized Diluted EPS | -0.90 | -1.02 | -1.08 | -1.50 | -1.76 |
| Average Basic Shares Outstanding | 151.68M | 131.74M | 110.70M | 81.42M | 66.35M |
| Average Diluted Shares Outstanding | 151.68M | 131.74M | 110.70M | 81.42M | 66.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |